// App-Quantinova.ai

: Maintenance of Skin Clearance in a Long-term Open-label Study of Fixed-Combination Halobetasol Propionate and Tazarotene Lotion for Psoriasis in Participants With Prior Use of Topical Treatments

Researchers

Presenter

  • Linda Stein Gold

Principal Investigators

  • Javier Alonso-Llamazares

  • Joshua Zeichner

  • Michael G. Lewitt

  • Abby Jacobson

Medical Centers

  • Henry Ford Hosp, Detroit, MI

  • Driven Research, Coral Gables, FL

  • Mount Sinai Hospital, New York, NY

  • Illinois Dermatology Institute, Chicago, IL

  • Ortho Dermatologics (a division of Bausch Health US, LLC), Bridgewater, NJ

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

  • Dermatology

Disease

  • Psoriasis

Biomarkers

  • Tafazzin

Drug/Treatment

  • Halobetasol propionate

  • Tazarotene

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • N/A

Study Id's

  • NCT02462083

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved